Lilly Q4 2022 EPS $2.14; revenue down 9%; core up 5%; 2023 guidance $7.90-$8.10

ELI LILLY & Co

2022-FY EPS reported $6.90 revenue$28,541,400,000

Q4 2022 revenue $7.30B (-9% YoY); ex-COVID antibodies revenue +5% (+10% constant currency).
Reported EPS $2.14 (+13%); non-GAAP EPS $2.09 (-4%); includes $0.23 acquired IPR&D charges.
Key growth products (Verzenio, Mounjaro, Jardiance, Taltz, Trulicity, etc.) grew 21% to 70% of revenue.
2023 EPS guidance: reported $7.90-$8.10; non-GAAP $8.35-$8.55; mid-teen core revenue growth expected.
Pipeline: FDA approved Jaypirca for MCL; rolling submission tirzepatide in obesity; Jardiance CKD submissions.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ELI LILLY & Co reported financial results for the quarter and year ended December 31, 2022.

Period: the quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February 2, 2023, announcing the financial results of Eli Lilly and Company for the quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

ELI LILLY & Co filing history →

Source: SEC EDGAR

accession 0000059478-23-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.